High circ_100053 predicts a poor outcome for chronic myeloid leukemia and is involved in imatinib resistance.
In this study, we aimed to investigate the expression profiling of circRNAs in CML. We performed circRNA-sequencing to identify differentially expressed circRNAs in CML cells. Furthermore, we found that circ_100053 was significantly upregulated in peripheral blood mononuclear cells (PBMC) and serum samples from CML compared with healthy controls. CircRNA_100053 expression was associated with clinical stage (p=0.037) and BCR/ABL mutant status (p=0.008). High circ_100053 expression predicted a poor outcome of CML patients and imatinib resistance, suggesting the putative role of circ_100053 as an CML biomarker. Our findings provide insights on circRNAs expression in the development and treatment of CML.
PMID: 30764894 [PubMed - as supplied by publisher]
Source: Oncology Research - Category: Cancer & Oncology Tags: Oncol Res Source Type: research
More News: Cancer & Oncology | Chronic Leukemia | Chronic Myeloid Leukaemia | Gleevec | Leukemia | Myeloproliferative Disorders | Study | Translocation